InvoX Pharma’s F-star Announces Licence Agreement With Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific Antibody
InvoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that F-star, an invoX company, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
- InvoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that F-star, an invoX company, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
- Under the terms of the licence agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing licence to research, develop, and commercialize a bispecific antibody directed towards an undisclosed immuno-oncology target using F-star’s proprietary Fcab™ and mAb2™ platforms.
- This licence agreement represents the second option that Takeda has exercised under an evaluation and licence agreement with F-star that was entered into in July 2021.
- F-star and Takeda entered into a licence agreement for a different bispecific antibody in July 2022.